Merck & Company ( (MRK) ) has released its Q1 earnings. Here is a breakdown of the information Merck & Company presented to its investors.
Merck & Company, known as MSD outside the United States and Canada, is a leading biopharmaceutical company that focuses on the development of medicines and vaccines across a wide range of therapeutic areas.
In the first quarter of 2025, Merck reported total worldwide sales of $15.5 billion, a 2% decrease from the previous year, though sales grew by 1% when excluding the impact of foreign exchange. Key products like KEYTRUDA saw a 4% increase in sales, while GARDASIL/GARDASIL 9 experienced a significant decline of 41% due to lower demand in China.
Merck’s financial performance was highlighted by a GAAP EPS of $2.01 and a non-GAAP EPS of $2.22. The company achieved several regulatory milestones, including approvals for new treatments and vaccines in various markets. Additionally, Merck expanded its pipeline through a license agreement with Hengrui Pharma for an investigational Lp(a) inhibitor.
Looking ahead, Merck maintains its full-year 2025 sales outlook between $64.1 billion and $65.6 billion, with a revised non-GAAP EPS expectation of $8.82 to $8.97. The company anticipates absorbing additional costs due to tariffs and a one-time charge related to its agreement with Hengrui Pharma.